| Code |
Title |
Intervention |
Sponsor |
Therapeutic Indication |
 |
| OLMITIAZ-02 |
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension
|
Olmesartan Medoxomil Hydrochlorothiazide 40/12.5 mg
vs Olmesartan Medoxomil 40 mg.
|
Menarini Ricerche S.p.A
|
Essential hypertension |
 |
| ABA-01 |
A Randomized, Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients with Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy
|
Abagovomab 2 mg/ml subcutaneous
vs Placebo subcutaneos
|
Menarini Ricerche S.p.A
|
Ovarian Cancer |
 |
| BCBE/05/NEB-PAO/088 |
Nebivolol vs Metoprolol in Hypertensive Patients with Peripheral Artery Occlusive Disease (PAOD)
|
Nebivolol 5 mg daily or Metoprolol 95 mg daily
|
Berlin Chemie AG
|
Hypertension and Peripheral Artery Occlusive Disease (PAOD) |
 |
| BCBe/04/Neb-Gla/081 |
Influence of Nebivolol on Ocular perfusion in patients with Glaucoma and arterial hypertension.
|
Nebivolol 5 mg vs Bisoprolol 5 mg
|
Berlin Chemie AG
|
Hypertension and Glaucoma |
 |
| Guid/05Met-GDM/001 |
Assessment of effects of a 12-month treatment with Metformin on Insulin action and secretion in women with prior gestational diabetes mellitus (GDM)
|
Metformin 850 mg
|
Laboratori Guidotti
|
Diabetes Mellitus |
 |
| MeFI/04/OBR-IBS/001 |
Otilonium Bromide in Irritable Bowel Syndrome (OBIS). Double blind, randomized, parallel group, placebo-controlled study to evaluate the effect of otilonium bromide on abdominal pain and quality of life in patients with irritable bowel syndrome
|
Otilonium bromide 40 mg tablets t.i.d before meals (120 mg OB7day) ,or machthing placebo
|
A.Menarini Farmaceutica Internazionale srl
|
Irritable Bowel Sindrome |
 |
| MeES/05/NeB-EnD/001 |
Comparison the effects of Nebivolol versus Metoprolol succinate on endothelial function and large artery Stiffness
|
Nebivolol 5 mg and Metoprolol 50-100 mg
|
OU Berlin Chemie Menarini Eesti
|
Hypertension |
 |
| BCBe/04/Neb-PAO/087 |
Effects of Nebivolol on the walking distance in patients with essential hypertension and peripheral arterial occlusive disease (PAOD) Fontaine's stage II-A randomized, double blind, multicenter, active substance controlled clinical trial phase III
|
Nebivolol 5 mg, HCTZ (hydrochlorothiazide) 25 mg
|
Berlin Chemie AG
|
Hypertension And Peripheral Arterial Occlusive Disease (PAOD) |
 |
| BCBe/04/Neb-Car/082 |
Comparison of the effects of combined rate and rhythm-control treatment with Nebivolol and electric cardioversion to rate- control treatment with Nebivolol alone on clinical and echocardiographic parameters in patients with Left ventricular dysfunction induced by tachycardia
|
Nebivolol 5 mg/ die
|
Berlin Chemie AG
|
Hypertension and Arrhythmia |
 |
| OLM/CLIN/I-12/03 |
Efficacy and Safety of Olmesartan in elderly patients with mild to moderate hypertension
|
Olmesartan 10/20/40 mg/die vs Ramipril 2,5/5/10 mg/die for 12 weeks; 36 weeks more for patient on Olmesartan 40 mg/die
|
Malesci Istituto Farmacologico S.p.A/Laboratori Guidotti S.p.A
|
Hypertension |
 |
| MeTK/CLIN/NEB/ HYPERTROPHY/03/001 |
Effects of Nebivolol and Ramipril on Left Ventricular Hypertrophy, Quality of Life and Blood Pressure in patients with mild to moderate hypertension associated to Left Ventricular Hypertropy
|
Nebivolol 5 mg/ die; Ramipril 5mg/die
|
I.E Ulagay Ilac Sanayii Turk AS
|
Hypertension Left ventricular Hypertrophy |
 |
| GUID/02/Glm-Dia/001 |
Comparative study on the efficacy and tolerability of a new combination og Glibenclamide (2,5 mg)+ Metformin (850mg) vs a standard combination of Glibenclamide (2,5 mg) + Metformin (400mg), vs monotherapy with Glibenclamide (5 mg) and vs monotherapy with Metformin (850mg), in the treatment of type 2 diabetes mellitus.
|
Glibenclamide ( 2,5 mg) + Metformin ( 850 mg) vs Glibenclamide (2,5 mg) + Metformin (400 mg) vs Glibenclamide (5mg) vs Metformin (850 mg)
|
Laboratori Guidotti S.p.A
|
Diabetes Mellitus |
 |
| MeBN/02/Zof-AMI/001(ZAAMIS) |
A multicenter, double-blind, randomized 2x2 factorial design study to compare the efficacy of early (< 6 hours) versus late (24-48 hours) ACE inhibition and to compare the efficacy of Zofenopril and Lisinopril on oxidative reperfusion injury after a first acute anterior myocardial infarction: ZAAMIS (Zofenopril After Acute Myocardial Infarction Study)
|
Zofenopril 30 mg twice daily
|
Menarini Benelux SA/NV
|
Acute Myocardial Infartcion |
 |
| MEN/03/ZOF-CHF/001 |
Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction. (SMILE IV trial)
|
Zofenopril
30 mg bid + ASA
vs.
Ramipril 5 mg bid + ASA
|
Menarini International Operations Luxemburg S.A., Laboratori Guidotti S.p.A. and Istituto Lusofarmaco d' Italia S.p.A.
|
Heart Failure Post Acute Myocardial Infarction |
 |
| MeIn/03/Olm-Hyp/001 |
Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension. Randomised, double blind, active-control study in two parallel groups of patients with mild to moderate hypertension
|
Olmesartan
10-40 mg, qd
vs.
Ramipril 2.5-10 mg, qd
|
Menarini International Operations Luxemburg S.A.
|
Hypertension |
 |
| IC01/03/DKP |
Multicentre clinical trial to evaluate the analgesic efficacy and safety of Dexketoprofen (50 mg t.i.d.) vs. Ketorolac (30 mg t.i.d.) by intravenous route as part of balanced analgesic therapy with morphine followed by oral dose administration in postoperative pain
|
Dexketoprofen
vs. Ketorolac
|
Laboratorios Menarini SA
|
Post surgical Pain |
 |
| IC01/04/DKP |
Multicentre clinical trial to evaluate the analgesic efficacy and safety of Dexketoprofen (50 mg iv single dose, followed by oral dose of 25 mg t.i.d.) vs. Metamizol (2 g iv single dose, and 575 mg t.i.d oral) for the treatment of pain subsequent to ambulatory surgery
|
Dexketoprofen
vs. Metamizol
|
Laboratorios Menarini SA
|
Post surgical Pain |
 |
| MeBN/02/Neb-DHF/001 |
Effects of The Long-Term Administration Of Nebivolol on the Clinical Symptoms, Exercise Capacity And Left Ventricular Function Of Patients With Diastolic Dysfunction (ELANDD)
|
Nebivolol,
5-10 mg, tablets
|
Menarini Benelux SA/NV
|
Heart Failure |
 |
| MeBN/02/Neb-PCI/002 |
Nebivolol inhibition of coronary artery Smooth muscle cell proliferation after Coronary artery InterventiOn (NESCIO)
|
Nebivolol,
5 mg, tablets
|
Menarini Benelux SA/NV
|
Angina pectoris post Acute Myocardial Infarction |
 |
| MeRo/04/Neb-LVD/001 |
Effects of Nebivolol on Subclinical left ventricular dysfunction. A comparative study against Metoprolol. (ENESYS)
|
Nebivolol,
5 mg,
tablets, qd
vs.
Metoprolol 50 mg, bid
|
Berlin-Chemie AG
|
Hypertension and Left Ventricular Dysfunction |
 |
| MEFI/05/DEX-MIG/01 |
Dexketoprofen Trometamol in the therapy of migraine
|
Dexketoprofen 25 mg
Vs
Dexketoprofen 50 mg
vs placebo
|
A Menarini IFR
|
Migraine |
 |
| MEIN/06/FRO-PP/002 |
A double-blind, cross-over patient preference study of frovatriptan versus rizatriptan for the acute treatment of migraine
|
Frovatriptan 2.5 mg
Vs Rizatriptan 10 mg
|
Menarini International Operations Luxemburg S.A
|
Migraine |
 |
| MEIN/06/FRO-PP/001 |
A Double-Blind, Cross-Over Patient Preference Study of Frovatriptan Versus Zolmitriptan for the Acute Treatment of Migraine
|
Frovatriptan 2.5 mg
Vs Zolmitriptan 2.5 mg
|
Menarini International Operations Luxemburg S.A
|
Migraine |
 |
| LUMI/06/FRO-MIG/002 |
Frovatriptan Versus Zolmitriptan in the Treatment of Migraine with or without Aura: a Patient Preference Study
|
Frovatriptan 2.5 mg
Vs Zolmitriptan 2.5 mg
|
Istituto Lusofarmaco d’Italia S.p.A.
|
Migraine |
 |
| LUMI/06/FRO-MIG/001 |
A patient preference study of frovatripitan versus rizatriptan for the acute treatment of migraine
|
Frovatriptan 2.5 mg
Vs Rizatriptan 10 mg
|
Istituto Lusofarmaco d’Italia S.p.A.
|
Migraine |
 |
| GUI/06/FRO-PP/002 |
A double-blind, cross-over patient preference study of frovatriptan versus almotriptan for the acute treatment of migraine
|
Frovatriptan 2.5 mg
Vs Almotriptan 12.5 mg
|
Laboratori Guidotti S.p.A.
|
Migraine |
 |
| MEFR/05/KET-RHU/001 |
A phase IV ramdomised, double-blind, double-dummy study in two parallel groups: KETUM 2.5 gel versus Diclofenac 50 mg per os in symtomatic osteoarthritis of the hand
|
Ketoprofen 2.5% gel t.i.d.
Vs Dicloflenac 150 mg o.d.
|
Menarini France S.A.
|
Osteoarthritis of the hand |
 |
| MEIN/06/OB-20/80/001 |
A dose-ranging study of otilonium bromide in patients with irritable bowel syndrome
|
Otilonium Bromide 20 or 40 or 80 mg t.i.d.
vs placebo
|
Menarini International Operations Luxemburg S.A.
|
Irritable bowel syndrome |
 |
| MEES/07/NEB-CBP/001 |
Effects of Nebivolol and Atenolol on Central Aortic Pressure in Hypertensive Patients (NEPAC)
|
Nebivolol 5 mg o.d.
vs Atenolol 50 mg or 100 mg o.d.
|
Menarini International Operations Luxemburg S.A.
|
Hypertension |
 |
| BCBE/07/NEB-SPACE/102 |
Effects of Nebivolol on the cardiovascular functions, thermoregulation and blood flow during real and simulated conditions of microgravity. MISSION Medicine in Space Study - Investigation on Nebivolol.
|
Nebivolol 5 mg o.d.
vs placebo
|
Berlin –Chemie A.G.
|
Microgravity cardiovascular dysfunctions |
 |
| NAK-03 (IRIS) |
Double-blind, randomised, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of men15596 in irritable bowel syndrome
|
Ibodutant oral tablet
|
Laboratorios Menarini S.A.-Menarini Group
|
|
 |